Corvus Pharmaceuticals (CRVS) News Today → Tim Sykes’ Urgent Trade Alert: “Make this move now” (From Timothy Sykes) (Ad) Free CRVS Stock Alerts $2.02 -0.04 (-1.94%) (As of 05/28/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 20, 2024 | stockhouse.comSHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Corvus Pharmaceuticals, Inc. (CRVS) and Encourages Investors to Contact the FirmMay 15, 2024 | marketbeat.comCorvus Pharmaceuticals (NASDAQ:CRVS) Shares Pass Above 50 Day Moving Average of $1.77Corvus Pharmaceuticals (NASDAQ:CRVS) Share Price Crosses Above 50-Day Moving Average of $1.77May 12, 2024 | finance.yahoo.com13 Penny Stocks with Insider Buying in 2024May 10, 2024 | finance.yahoo.comInsider Spends US$1m Buying More Shares In Corvus PharmaceuticalsMay 8, 2024 | insidertrades.comCorvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Insider Purchases $34,600.00 in StockMay 7, 2024 | marketbeat.comWilliam Benton Jones Purchases 20,000 Shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) StockCorvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Get Free Report) insider William Benton Jones acquired 20,000 shares of the stock in a transaction dated Monday, May 6th. The shares were purchased at an average price of $1.73 per share, for a total transaction of $34,600.00. Following the completion of the transaction, the insider now owns 153,773 shares of the company's stock, valued at approximately $266,027.29. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.May 7, 2024 | finance.yahoo.comCorvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q1 2024 Earnings Call TranscriptMay 7, 2024 | finanznachrichten.deCorvus Pharmaceuticals, Inc.: Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial ResultsMay 7, 2024 | finance.yahoo.comQ1 2024 Corvus Pharmaceuticals Inc Earnings CallMay 7, 2024 | marketbeat.comOppenheimer Increases Corvus Pharmaceuticals (NASDAQ:CRVS) Price Target to $8.00Oppenheimer upped their target price on shares of Corvus Pharmaceuticals from $7.00 to $8.00 and gave the stock an "outperform" rating in a research report on Tuesday.May 7, 2024 | finance.yahoo.comCorvus Pharmaceuticals Inc (CRVS) Q1 2024 Earnings Call Transcript Highlights: Strategic ...May 6, 2024 | globenewswire.comCorvus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial ResultsMay 3, 2024 | marketbeat.comCorvus Pharmaceuticals (CRVS) Set to Announce Earnings on MondayCorvus Pharmaceuticals (NASDAQ:CRVS) will be releasing earnings after the market closes on Monday, May 6, Zacks reports.May 2, 2024 | globenewswire.comCorvus Pharmaceuticals to Provide Business Update and First Quarter 2024 Financial Results on May 6, 2024May 2, 2024 | globenewswire.comCorvus Pharmaceuticals Announces Pricing of $30.6 Million Registered Direct OfferingApril 24, 2024 | finance.yahoo.comCorvus Pharmaceuticals, Inc. (CRVS)April 17, 2024 | finance.yahoo.comHere's Why Corvus (CRVS) is Poised for a Turnaround After Losing -25% in 4 WeeksApril 16, 2024 | marketbeat.comCorvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Short Interest Down 6.0% in MarchCorvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Get Free Report) was the target of a significant decrease in short interest during the month of March. As of March 31st, there was short interest totalling 1,400,000 shares, a decrease of 6.0% from the March 15th total of 1,490,000 shares. Currently, 3.8% of the shares of the stock are sold short. Based on an average trading volume of 212,900 shares, the days-to-cover ratio is currently 6.6 days.April 9, 2024 | globenewswire.comCorvus Pharmaceuticals Announces Initiation of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic DermatitisApril 4, 2024 | marketbeat.comCorvus Pharmaceuticals, Inc. to Post FY2024 Earnings of ($0.35) Per Share, Cantor Fitzgerald Forecasts (NASDAQ:CRVS)Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Free Report) - Research analysts at Cantor Fitzgerald lifted their FY2024 EPS estimates for shares of Corvus Pharmaceuticals in a report issued on Monday, April 1st. Cantor Fitzgerald analyst L. Watsek now forecasts that the company will earn ($0.35) peApril 1, 2024 | marketbeat.comCantor Fitzgerald Reaffirms Overweight Rating for Corvus Pharmaceuticals (NASDAQ:CRVS)Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Corvus Pharmaceuticals in a research note on Monday.March 27, 2024 | marketbeat.comMizuho Reiterates Neutral Rating for Corvus Pharmaceuticals (NASDAQ:CRVS)Mizuho reaffirmed a "neutral" rating and set a $3.50 target price on shares of Corvus Pharmaceuticals in a research report on Wednesday.March 21, 2024 | seekingalpha.comCorvus Pharmaceuticals, Inc. (CRVS) Q4 2023 Earnings Call TranscriptMarch 21, 2024 | finance.yahoo.comCorvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q4 2023 Earnings Call TranscriptMarch 21, 2024 | finanznachrichten.deCorvus Pharmaceuticals, Inc.: Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial ResultsMarch 20, 2024 | marketbeat.comCorvus Pharmaceuticals (NASDAQ:CRVS) Price Target Lowered to $7.00 at OppenheimerOppenheimer cut their price target on Corvus Pharmaceuticals from $8.00 to $7.00 and set an "outperform" rating for the company in a research note on Wednesday.March 20, 2024 | finance.yahoo.comQ4 2023 Corvus Pharmaceuticals Inc Earnings CallMarch 19, 2024 | stockhouse.comCorvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial ResultsMarch 19, 2024 | globenewswire.comCorvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial ResultsMarch 18, 2024 | marketbeat.comCorvus Pharmaceuticals (CRVS) Set to Announce Quarterly Earnings on TuesdayCorvus Pharmaceuticals (NASDAQ:CRVS) will be releasing earnings on Tuesday, March 19, Yahoo Finance reports.March 16, 2024 | finance.yahoo.comCRVS Apr 2024 4.000 putMarch 13, 2024 | globenewswire.comCorvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2023 Financial Results on March 19, 2024March 9, 2024 | finance.yahoo.comWe Think Corvus Pharmaceuticals (NASDAQ:CRVS) Needs To Drive Business Growth CarefullyMarch 4, 2024 | marketbeat.comCorvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Short Interest Down 8.0% in FebruaryCorvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Get Free Report) was the target of a large decline in short interest in February. As of February 15th, there was short interest totalling 1,270,000 shares, a decline of 8.0% from the January 31st total of 1,380,000 shares. Approximately 3.4% of the shares of the stock are short sold. Based on an average trading volume of 206,300 shares, the short-interest ratio is currently 6.2 days.February 17, 2024 | finance.yahoo.comCRVS Mar 2024 3.000 putFebruary 12, 2024 | msn.comCorvus Edges up on Disclosing DataFebruary 12, 2024 | finance.yahoo.comCorvus' (CRVS) Lymphoma Drug Gets Orphan Status, Stock UpFebruary 8, 2024 | marketwatch.comCorvus Pharmaceuticals Shares Rise on Orphan Drug DesignationFebruary 8, 2024 | msn.comCorvus lymphoma drug gets FDA orphan drug statusFebruary 8, 2024 | finance.yahoo.comCorvus Pharmaceuticals Announces Orphan Drug Designation Granted to Soquelitinib for the Treatment of T Cell LymphomaFebruary 6, 2024 | finance.yahoo.comCorvus Pharmaceuticals Appoints Jeffrey Arcara as Chief Business OfficerJanuary 23, 2024 | finance.yahoo.comCorvus Pharmaceuticals Announces the Passing of Board Member Edith P. MitchellJanuary 5, 2024 | finance.yahoo.comIndividual investors in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) are its biggest bettors, and their bets paid off as stock gained 20% last weekDecember 13, 2023 | markets.businessinsider.comMaintaining Hold Rating on Corvus Pharmaceuticals Amid Steady but Unspectacular Clinical ProgressDecember 7, 2023 | msn.comAre Medical Stocks Lagging Corvus Pharmaceuticals (CRVS) This Year?November 21, 2023 | finance.yahoo.comIs Corvus Pharmaceuticals (CRVS) Stock Outpacing Its Medical Peers This Year?November 9, 2023 | morningstar.comCorvus Pharmaceuticals Inc CRVSNovember 8, 2023 | finance.yahoo.comCorvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q3 2023 Earnings Call TranscriptNovember 8, 2023 | finance.yahoo.comQ3 2023 Corvus Pharmaceuticals Inc Earnings CallNovember 7, 2023 | finance.yahoo.comCorvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2023 Financial Results Get Corvus Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CRVS and its competitors with MarketBeat's FREE daily newsletter. Email Address Nvidia’s Quiet $1 Trillion Pivot (Ad)Nvidia recently added $277 billion in market cap … IN ONE DAY. Find out details on these three critical Nvidia partners immediately. CRVS Media Mentions By Week CRVS Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CRVS News Sentiment▼1.880.86▲Average Medical News Sentiment CRVS News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CRVS Articles This Week▼31▲CRVS Articles Average Week Get Corvus Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CRVS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Genelux News Seres Therapeutics News scPharmaceuticals News Adicet Bio News Citius Pharmaceuticals News Karyopharm Therapeutics News Regulus Therapeutics News Cartesian Therapeutics News OptiNose News Renovaro News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CRVS) was last updated on 5/28/2024 by MarketBeat.com Staff From Our PartnersThe #1 Crypto That You Don’t Own… YetCrypto 101 MediaWARNING about the death of the U.S. dollar…Colonial MetalsExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersTim Sykes’ Urgent Trade Alert: “Make this move now”Timothy SykesHe Is Giving Away BitcoinCrypto Swap ProfitsMissed NVDA? Buy this AI stock NOWChaikin AnalyticsDigitizing the $11T commodities sector with one tiny stockResource Stock DigestElon’s New Device is About to Shock the WorldInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Corvus Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.